Navigation Links
Steno 'Superbug' Genome Shows Extreme Drug Resistance

Blood poisoner has claimed the lives of 30% of infected patients in U.K., researchers say

FRIDAY, May 9 (HealthDay News) British research into Steno, one the most recent "superbugs" to claim lives, reveals that the bacterium has an incredible ability to resist antibiotics and other drugs, according to soon-to-be-published findings.

Steno, short for Stenotrophomonas maltophilia, thrives in moist environments, such as around taps and shower heads, and can be transmitted to people. It is responsible for roughly 1,000 cases of Steno blood poisoning in the U.K. annually. About 30 percent of these infections prove fatal.

"This is the latest in an ever-increasing list of antibiotic-resistant hospital superbugs. The degree of resistance it shows is very worrying," study senior author Dr. Matthew Avison, of the University of Bristol, said in a prepared statement. "Strains are now emerging that are resistant to all available antibiotics, and no new drugs capable of combating these pan-resistant strains are currently in development."

Pan-resistant Steno infections are extremely hard to treat but are rarer than similarly difficult MRSA and Clostridium difficile infections and are exclusively hospital-acquired.

The paper, to be published in Genome Biology, discusses the findings when researchers recently sequenced the Steno genome. This process, they hope, will help them learn how this bacterium works, so they can discover how to best combat it.

The organism, which is also found in the lungs of many adults with cystic fibrosis, can cause pneumonia and septicemia. Steno only enters the body through devices, such as catheters or ventilation tubes, which are left in place for long periods of time. It sticks to the catheter, grows into a 'biofilm,' and enters the patient's bloodstream when the catheter is next flushed.

Steno often affects the seriously ill, whose immune systems are already weakened. Since the new research shows Steno to be largely resistant to antibiotics, these patients face an extremely difficult situation.

"The genome sequence should help us to combat these properties," lead author Dr. Lisa Crossman, of the Wellcome Trust Sanger Institute near Cambridge, said in a prepared statement. "For example, if we know which proteins cause it to stick to surfaces, we could try to develop biochemical compounds that interfere with this interaction. If we understand its antibiotic resistance mechanisms, we might be able to design inhibitors that block them."

Researchers also hope that since Steno causes similar types of infections to two more common organisms, they can find solutions by comparing the two.

"Genome sequences for these two also exist, and so now we can look at what they all have in common genetically that might explain why they are so resistant to antibiotics," Avison said.

More information

The U.S. Centers for Disease Control has more about drug-resistant bacteria.

-- Kevin McKeever

SOURCE: University of Bristol, news release, May 7, 2008

Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Investigational anti-restenosis drug pimecrolimus disappoints
2. Drug-coated balloon overcomes in-stent restenosis
3. Superbug genome sequenced
4. Green Tea Boosts Antibiotics for Superbugs
5. Scientists uncover how superbug Staph aureus resists our natural defenses
6. Some Facelift Patients Infected With MRSA Superbug
7. Scientists strike blow in superbugs struggle
8. Six Simple Steps to Protect Against and Stop the Spread of Superbugs
9. Biomist Inc.: Health Officials Discover New Technology to Kill Superbug MRSA
10. Key Cleaning Solutions Products Utilized to Combat Community Acquired - MRSA (CA-MRSA) Are Succeeding In Killing Superbugs Where Normal Cleaning Practices and Products Are Not
11. The Environmentally Friendly Superbug Killer
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/26/2016)... ... 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing ... their videos a whole new perspective by using the title layers in ProSlice ... , ProSlice Levels contains over 30 Different presets to choose from. FCPX ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
Breaking Medicine Technology: